CSIMarket
 


Nymox Pharmaceutical Corporation  (NYMX)
Other Ticker:  
 
 

NYMX's EPS from Cont. Operations Growth by Quarter and Year

Nymox Pharmaceutical's EPS from Cont. Operations results by quarter and year




NYMX EPS from Cont. Operations (in $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December -0.07 -0.15 -0.16 -0.19
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   -0.07 -0.15 -0.16 -0.19



NYMX EPS from Cont. Operations fourth quarter 2022 Y/Y Growth Comment
Nymox Pharmaceutical Corporation in the fourth quarter 2022 recorded EPS loss from Cont. Operations of $ -0.07 .

According to the results reported in the fourth quarter 2022, Nymox Pharmaceutical Corporation achieved the best EPS from Cont. Operations growth in In Vitro & In Vivo Diagnostic Substances industry. While Nymox Pharmaceutical Corporation' s EPS from Cont. Operations no change of % ranks overall at the positon no. in the fourth quarter 2022.




NYMX EPS from Cont. Operations ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Nymox Pharmaceutical's fourth quarter 2022 EPS from Cont. Operations $ -0.07 NYMX's Income Statement
Nymox Pharmaceutical's fourth quarter 2021 EPS from Cont. Operations $ -0.15 Quarterly NYMX's Income Statement
New: More NYMX's historic EPS from Cont. Operations Growth >>


NYMX EPS from Cont. Operations (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




EPS from Cont. Operations fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
EPS from Cont. Operations fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

EPS from Cont. Operations by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Nymox Pharmaceutical's Q/Q EPS from Cont. Operations Growth


EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NYMX's IV. Quarter Q/Q EPS from Cont. Operations Comment


EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Q/Q Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #
EPS from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


NYMX's IV. Quarter Q/Q EPS from Cont. Operations Comment


Nymox Pharmaceutical's 12 Months EPS from Cont. Operations Growth Year on Year


EPS from Cont. Operations TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
0
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
Cumulative EPS from Cont. Operations 12 Months Ending $ -0.07 $ 0.00 $ 0.00 $ 0.00 $ -0.15
Y / Y EPS from Cont. Operations Growth (TTM) - - - - -
Year on Year EPS from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential EPS from Cont. Operations Change (TTM) - - - - -
Seq. EPS from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative EPS from Cont. Operations growth Comment


Nymox Pharmaceutical Corporation achieved highest trailing twelve month year on year EPS from Cont. Operations growth. While overall EPS from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative EPS from Cont. Operations growth Comment


Nymox Pharmaceutical Corporation achieved highest trailing twelve month year on year EPS from Cont. Operations growth. While overall EPS from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

EPS from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry #
Healthcare Sector #
Overall #

EPS from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


EPS from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other EPS from Cont. Operations Growth
In Vitro & In Vivo Diagnostic Substances Industry EPS from Cont. Operations Growth Trends and Statistics
Healthcare Sector EPS from Cont. Operations Growth Statistics
EPS from Cont. Operations Growth Trends for overall market
NYMX's EPS from Cont. Operations Growth Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking EPS from Cont. Operations Growth
Lowest Ranking EPS from Cont. Operations Growth
EPS from Cont. Operations Growth for NYMX's Competitors
EPS from Cont. Operations Growth for Nymox Pharmaceutical's Suppliers
EPS from Cont. Operations Growth for NYMX's Customers

You may also want to know
NYMX's Annual Growth Rates NYMX's Profitability Ratios NYMX's Asset Turnover Ratio NYMX's Dividend Growth
NYMX's Roe NYMX's Valuation Ratios NYMX's Financial Strength Ratios NYMX's Dividend Payout Ratio
NYMX's Roa NYMX's Inventory Turnover Ratio NYMX's Growth Rates NYMX's Dividend Comparisons



Companies with similar EPS from Cont. Operations no change for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %EPS from Cont. Operations for the quarter ending Dec 31 2022
Encompass Health Corporation-2.60%$ -2.599 
Inmode Ltd -3.45%$ -3.448 
Vanda Pharmaceuticals Inc -4.54%$ -4.543 
Amedisys Inc -6.60%$ -6.603 
Iradimed Corporation-6.71%$ -6.706 
Vascular Biogenics Ltd -7.44%$ -7.437 
Eton Pharmaceuticals Inc -8.34%$ -8.343 
Lemaitre Vascular Inc -9.47%$ -9.470 
Amgen Inc -10.28%$ -10.281 
Polypid Ltd -10.53%$ -10.526 
Alcon inc -11.69%$ -11.688 
Bristol myers Squibb Company-12.06%$ -12.060 
Intuitive Surgical Inc -13.05%$ -13.054 
Acadia Healthcare Company Inc -13.87%$ -13.872 
Steris Plc-13.89%$ -13.889 
Stryker Corp-14.98%$ -14.980 
Envista Holdings Corporation-15.28%$ -15.279 
Pharming Group N v -16.00%$ -16.000 
Qiagen N v -17.33%$ -17.333 
Uniqure N v -18.15%$ -18.153 
Universal Health Services Inc -19.04%$ -19.040 
Merck and Co Inc -19.65%$ -19.652 
Chemed Corporation-21.29%$ -21.292 
Atrion Corporation-21.89%$ -21.886 
Orgenesis Inc -22.47%$ -22.472 
Integer Holdings Corporation-24.16%$ -24.155 
Baxter International Inc -24.70%$ -24.703 
Integrated Biopharma Inc-25.00%$ -25.000 
Becton Dickinson And Company-25.65%$ -25.652 
Syneos Health Inc -26.32%$ -26.321 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com